COMPANY RESEARCHOral drug product services include preformulation, dosage form development, bioavailability enhancement, and clinical-to-commercial supply, with disclosed ASD and dissolution development services.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Offers mRNA/LNP process and analytical development and clinical and small-scale commercial manufacturing. Geleen integrates RNA and LNP production.
Oral drug product services include preformulation, dosage form development, bioavailability enhancement, and clinical-to-commercial supply, with disclosed ASD and dissolution development services.
The service page lists salt, polymorph, and cocrystal screening linked to crystallization development.
Biologics analytical development, characterization and GMP testing
Integrated CRO/CDMO analytical services
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| RNA / LNP service capabilities | Project-dependent / not verified · Project-dependent / not verified | Services / platform | This record does not establish human validation of the entire platform |
| Formulation development / contract manufacturing capabilities | Defined by the client project · Defined by the client project | Services / platform | Service pages do not establish human evidence for every project |
| Solid-state R&D capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Lonza signed an agreement to acquire five US CDMO sites from Merck KGaA, adding bioconjugation, payload-linker, viral vector, and advanced delivery capabilities. Closing is expected in mid-2027, subject to customary conditions. Until then, the businesses will continue operating independently.
Lonza announced three planned multiproduct bioconjugation suites in Visp, with operations expected from 2028, alongside 500-liter single-use upgrades scheduled for 2027. A November 2 update revised the new facility's maximum scale from 1,200 to 3,000 liters. The capacity remains under development; the announcement does not establish available current commercial slots.
Lonza expanded its accelerated DNA-to-IND offering to bispecific antibodies, Fc-fusion proteins, and high-concentration drug product formulations. The program coordinates drug substance and drug product development and manufacturing. Lonza states that eligible programs can deliver toxicology drug substance in as little as three months and reach IND readiness in six months; these are supplier-reported timelines.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.